← Back to Clinical Trials
Recruiting NCT07531342

NCT07531342 Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07531342
Status Recruiting
Phase
Sponsor Cairo University
Condition Crohn's Disease
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-01-01
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Repetitive transcranial magnetic stimulationAnti-inflammatory diet

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-01-01 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Fifty six patients with Crohn's disease of both genders with age 40 - 60 year old suffering from constipation, physical and functional limitations participated in this study. The participants were selected from Outpatient clinic of Faculty of Physical Therapy, Suez Canal University, Egypt and randomly distributed into two groups equal in number. Group (A): 25 patients who received rTMS 5 times per week in addition to anti-inflammatory diet for 4 weeks. While, Group (B): 25 patients received anti-inflammatory diet program for 4 weeks. Primary outcome measures were Quality of life questionnaire and Constipation severity index while Interlukins inflammatory markers was the secondary outcome measure.

Eligibility Criteria

Inclusion Criteria: * (1) Patients' age was ranged between 40-60 years old, (2) Both gender 50 patients participated in this study, (3) moderately to severely active refractory CD \> 4 months after diagnosis, (4) All the patients were free from genitourinary infections, (5) Neurologically free patient, (6) Patients who were able to comprehend command and willing to participate in the study, (7) Informed consent was obtained from all patients enrolled in the trial, (8) Clinical diagnosis of Alzheimer's Disease and (9) Must be able to swallow tablets. Exclusion Criteria: * (1) Epilepsy or seizures, (2) Metal implants in the head, skull, or neck, (3) Implanted medical devices, (4) Severe traumatic brain injury, (5) Skull fracture, (6) brain surgery, (7) Any neurological disorders that may increase risk, (8) severe cardiovascular conditions, (9) severe psychiatric disorders, (10) skin lesions, infections, (11) significant dermatological conditions at the electrode placement sites on the scalp, (12) Insulin dependent diabetes and (13) Thyroid disease.

Contact & Investigator

Central Contact

Mona Amin, PHD

✉ monaamin028@gmail.com

📞 01151602624

Principal Investigator

Research Ethical Committee Faculty of Physical Therapy

PRINCIPAL INVESTIGATOR

Cairo University

Frequently Asked Questions

Who can join the NCT07531342 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 60 Years, studying Crohn's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07531342 currently recruiting?

Yes, NCT07531342 is actively recruiting participants. Contact the research team at monaamin028@gmail.com for enrollment information.

Where is the NCT07531342 trial being conducted?

This trial is being conducted at Giza, Egypt.

Who is sponsoring the NCT07531342 clinical trial?

NCT07531342 is sponsored by Cairo University. The principal investigator is Research Ethical Committee Faculty of Physical Therapy at Cairo University. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology